Lantern Pharma's LP-300 Shows Deepening PFS Benefit with Extended Treatment in L858R NSCLC
Event summary
- Lantern Pharma reported Phase 2 HARMONIC™ trial data showing LP-300's progression-free survival (PFS) benefit deepens with longer treatment duration in EGFR Exon 21 L858R NSCLC patients.
- Median PFS reached 8.9 months in L858R patients treated for up to six cycles, with a 77% clinical benefit rate and durable responses beyond two years in select patients.
- LP-300 demonstrated a favorable safety profile compared to amivantamab-plus-chemotherapy, with lower rates of serious adverse events and infusion-related reactions.
- FDA cleared a protocol amendment extending LP-300 dosing from six to eight cycles, reinforcing focus on the L858R subgroup, which represents 40% of EGFR-mutated NSCLC patients globally.
The big picture
Lantern Pharma's data suggests LP-300 could carve out a niche in the EGFR Exon 21 L858R NSCLC space, where existing therapies like amivantamab face tolerability challenges. The AI-driven approach to drug development highlights a broader industry trend toward precision oncology, where biomarker-driven patient selection and machine learning are reshaping clinical trial design and therapeutic targeting. The strategic focus on the L858R subgroup underscores the company's commitment to addressing unmet needs in a molecularly defined patient population.
What we're watching
- Clinical Validation
- Whether the deepening PFS benefit observed with extended LP-300 treatment will be sustained in larger, confirmatory studies.
- Regulatory Strategy
- The pace at which Lantern Pharma advances LP-300 through subsequent clinical phases and potential regulatory filings.
- Commercial Potential
- How Lantern Pharma leverages the differentiated safety and efficacy profile of LP-300 to attract licensing and co-development partners.
Related topics